Current Status and Future of Cannabis Research

@article{Russo2015CurrentSA,
  title={Current Status and Future of Cannabis Research},
  author={Ethan B Russo and Alice P. Mead and Dustin Sulak},
  journal={Clinical researcher},
  year={2015},
  volume={29},
  pages={58-63}
}
Cannabis sativa has a long history of medicinal use and contains phytocannabinoids that demonstrate therapeutic activity in preclinical models of numerous disease states. Widespread clinical use of cannabis has preceded the evidence base. Randomized controlled trials are needed to understand the safety, efficacy, and optimal dosages of standardized cannabis preparations. In addition to regulatory and legal challenges,certain botanical and pharmacologic factors that complicate the collection and… 

Beyond Cannabis: Plants and the Endocannabinoid System.

Cannabis Therapeutics and the Future of Neurology

The inherent polypharmaceutical properties of cannabis botanicals offer distinct advantages over the current single-target pharmaceutical model and portend to revolutionize neurological treatment into a new reality of effective interventional and even preventative treatment.

History of Cannabis as Medicine: Nineteenth Century Irish Physicians and Correlations of Their Observations to Modern Research

The venerable Irish tradition of cannabis research is being carried on contemporaneously by numerous prominent scientists with the promise of important advancements yet to come.

Chapter 2 History of Cannabis as Medicine : Nineteenth Century Irish Physicians and Correlations of Their Observations to Modern Research

The venerable Irish tradition of cannabis research is being carried on contemporaneously by numerous prominent scientists with the promise of important advancements yet to come.

Clinical applications of hallucinogens: A review.

This review will present data on several classes of hallucinogens with a particular focus on psychedelics, entactogens, and dissociatives, for which clinical utility has been most extensively documented, with important ramifications for their potential therapeutic value.

What Do You Know About Maryjane? A Systematic Review of the Current Data on the THC:CBD Ratio

The medical and scientific communities have not drawn substantive conclusions nor thoroughly explored THC:CBD ratios for “best practice” treatment of different disease processes and their sequelae.

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes

This theory was based on genetic overlap and comorbidity, patterns of symptomatology that could be mediated by the endocannabinoid system (ECS), and the fact that exogenous cannabinoid treatment frequently provided symptomatic benefit, but objective proof and formal clinical trial data were lacking.

Fighting to survive: how supply chain managers navigate the emerging legal cannabis industry

The cannabis industry is a new quasi-legal industry Growing, selling and using cannabis are still illegal in most countries However, twenty-four countries and thirty-three U S states have approved

Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues

This overview covers a wide range of cannabis topics, initially examining issues in dispensaries and self-administration, plus regulatory requirements for production of cannabis-based medicines,

References

SHOWING 1-10 OF 46 REFERENCES

History of Cannabis and Its Preparations in Saga, Science, and Sobriquet

This most versatile botanical has provided a mirror to medicine and has pointed the way in the last two decades toward a host of medical challenges from analgesia to weight loss through the discovery of its myriad biochemical attributes and the endocannabinoid system wherein many of its components operate.

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic‐ischemic encephalopathy, however, data from well‐powered double‐blind randomized, controlled studies on the efficacy of pure CBD for any disorder is lacking.

Cannabis and psychiatric disorders: it is not only addiction

It became apparent that cannabis use is not only frequent in patients suffering from BD, but that it also induces manic symptoms in this group and cannabinoid compounds could display a new class of medication, as suggested by the fatty acid amino hydrolase inhibitor URB597 in animal models.

Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study

The antagonistic effects of cannabidiol at the CB1 receptor are probably responsible for its profile in smoked cannabis, attenuating the memory-impairing effects of THC.

Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis

Hair samples were analysed to examine levels of Δ9-THC and CBD in 140 individuals and three clear groups emerged: ’THC only’, ‘THC+CBD’ and those with no cannabinoid in hair, which provides evidence of the divergent properties of cannabinoids.

A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Health aspects of cannabis.

Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.

Compared with placebo, CBM added to standard anti-emetic therapy was well tolerated and provided better protection against delayed CINV.